What are the indications, dosing regimens, contraindications, adverse effects, monitoring recommendations, and alternative therapies for medroxyprogesterone acetate (Depo‑Provera)?

Medroxyprogesterone Acetate (Depo-Provera): Clinical Overview

Indications

Medroxyprogesterone acetate injectable suspension is indicated solely for pregnancy prevention and should be administered every 13 weeks. 1

Additional uses include:

• Endometrial protection in hormone replacement therapy for women with premature ovarian insufficiency who have not undergone hysterectomy 2
• Management of endometriosis-related pain (DMPA-SC formulation) 3

Dosing Regimens

Contraceptive Use

• 150 mg intramuscularly every 13 weeks (standard formulation) 4, 5, 1
• 104 mg subcutaneously every 13 weeks (DMPA-SC) 4, 5
• Grace period: Up to 2 weeks late (15 weeks total) without requiring backup contraception 4, 5, 6
• If >2 weeks late: Administer only if reasonably certain patient is not pregnant; require abstinence or backup contraception for 7 days 5

Self-Administration Option

• The 104 mg subcutaneous formulation can be prescribed for off-label self-administration after proper instruction on injection technique, sharps disposal, and with access to follow-up care 4, 5
• Self-administration improves access and reproductive autonomy with higher continuation rates 4

Hormone Replacement Therapy Use

For women with premature ovarian insufficiency:

• Sequential regimen: 10 mg oral medroxyprogesterone acetate for 12-14 days per month when combined with continuous estrogen 2
• Continuous regimen: 2.5 mg oral medroxyprogesterone acetate daily 2
• Medroxyprogesterone acetate is the only progestin with demonstrated full effectiveness in inducing secretory endometrium when used with full replacement estrogen doses 2

Contraindications

Absolute Contraindications (FDA-Labeled)

• Known or suspected pregnancy 7
• Undiagnosed vaginal bleeding 7
• Known or suspected breast malignancy 7
• Active thrombophlebitis, current or past thromboembolic disorders, or cerebrovascular disease 7
• Liver dysfunction or disease 7
• Known hypersensitivity to medroxyprogesterone acetate 7

Additional Contraindications from Guidelines

• History of stroke or myocardial infarction 4
• Pulmonary embolism or deep vein thrombosis 4
• History of meningiomas 5

NOT Contraindications (Common Pitfall)

• HIV infection, immunosuppression, pelvic inflammatory disease history, and adolescent age are NOT contraindications 4, 5

Pre-Initiation Requirements

No physical examination, pelvic exam, or laboratory tests are required before starting DMPA. 4

• Start at any time if reasonably certain patient is not pregnant 4
• Backup contraception for 7 days if initiated >7 days after menses started 4
• Screen for contraindications listed above 5

Adverse Effects

Menstrual Changes (Most Common)

• Nearly all users experience menstrual irregularities initially, typically irregular spotting and bleeding, particularly during the first year 8, 9
• With continued use, spotting decreases and amenorrhea becomes common 8, 10
• Thorough pre-injection counseling about bleeding patterns markedly reduces discontinuation rates 6

Weight Changes

• Weight gain is a potential side effect 4, 9
• Weight gain >5% at 6 months signals higher risk for continued significant weight increase 6
• Similar weight changes observed in obese and non-obese users 3

Bone Mineral Density

• Prolonged DMPA use is associated with reversible reduction in bone density, related to suppression of endogenous estrogen production 8
• The FDA black-box warning states concerns about long-term use (>2 years), though ACOG emphasizes that benefits of pregnancy prevention generally outweigh bone density risks 4, 6
• Bone density changes are reversible after discontinuation 8

Metabolic Effects

• Long-term use induces moderate unfavorable changes in lipid metabolism regarding atherosclerosis risk 8
• Medroxyprogesterone acetate 20 mg daily (HRT dose) reduces HDL cholesterol and may increase cardiovascular risk 11
• Lower doses (10 mg) may not adversely affect lipids 11

Fertility Return

• Ovulation suppression may persist for up to 18 months after the last injection, though this does not permanently affect fertility 8
• Return to fertility is delayed several months after discontinuation 10

Beneficial Effects

• Reduces menstrual blood loss 8
• Decreased incidence of candidal vulvovaginitis and pelvic inflammatory disease 8
• Dramatically lowers risk of endometrial cancer 8
• Improves endometriosis-related pain symptoms 3

Monitoring Recommendations

At Each Visit (Every 13 Weeks)

• Assess patient satisfaction and concerns 5
• Evaluate for new medical conditions that would change appropriateness of DMPA based on U.S. Medical Eligibility Criteria 5
• Monitor weight changes and counsel patients concerned about weight 5
• Screen for new contraindications (stroke, MI, PE, DVT, meningiomas) 5

Routine Follow-Up

• No routine follow-up visits are required between scheduled injections 5, 6
• Patients should be encouraged to contact provider for side effects, desire to change methods, or injection concerns 5, 6
• Many clinicians schedule appointments at 11-12 weeks to provide buffer for missed injections 6

Bone Health Counseling (Essential for All Users)

• Daily calcium intake ≥1,300 mg 5, 6
• Vitamin D 600 IU daily 5, 6
• Regular weight-bearing exercise 4, 5, 6
• Smoking cessation and alcohol avoidance 5

Long-Term Use Considerations

• For use beyond 2 years, counsel on skeletal health measures 4
• Bone mineral density assessment should be considered when prolonged use is contemplated 6
• DMPA should not be limited to 2 years based solely on bone density concerns, as benefits of pregnancy prevention outweigh risks 5, 6

STI Protection

• Counsel patients to use condoms for STI protection, as DMPA provides no protection against sexually transmitted infections 5

Alternative Therapies

For Contraception

The contraceptive efficacy of DMPA (failure rate 0-0.7%) is comparable to modern copper IUDs and superior to many other methods 1, 9

Alternative long-acting reversible contraceptives include:

• Levonorgestrel intrauterine device (failure rate 0.8%) 1
• Copper T 380A IUD (failure rate 0.8%) 1
• Implants (Norplant: failure rate 0.2%) 1

For Hormone Replacement Therapy in Premature Ovarian Insufficiency

• Micronized progesterone is the first-choice progestin due to favorable cardiovascular and thrombotic risk profile 2
• Dydrogesterone is listed as a suggested alternative 2
• Norethisterone acetate has a less favorable safety profile regarding blood pressure and renal function 2
• Avoid progestins with anti-androgenic effects in cancer survivors with iatrogenic POI due to risk of worsening hypoandrogenism 2

For Endometriosis/Adenomyosis

• Levonorgestrel IUD offers effective menstrual suppression without bone density concerns and is considered superior first-line for patients requiring contraception 6
• Combined oral contraceptives, GnRH agonists, and aromatase inhibitors have more established efficacy 6
• Hysterectomy remains definitive treatment for refractory cases 6

Common Pitfalls to Avoid

• Do not require routine follow-up visits between injections 5, 6
• Do not limit use to 2 years based solely on bone density concerns 5, 6
• Do not withhold from adolescents, HIV-positive patients, or those with PID history 4, 5
• Do not administer monthly—this would cause drug accumulation and lacks safety/efficacy data 6
• Do not skip pre-injection counseling about bleeding patterns—this dramatically reduces discontinuation 6
• Do not forget to assess baseline weight for future comparison 4